NCT00256191View on ClinicalTrials.gov

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

February 28, 2007

Conditions
NeoplasmsHodgkin's DiseaseNon-Hodgkin's Lymphoma
Interventions
DRUG

TPI 287 Injection

Trial Locations (1)

80218

Rocky Mountain Cancer Center, Denver

Sponsors
All Listed Sponsors
lead

Cortice Biosciences, Inc.

INDUSTRY

NCT00256191 - Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter